Navigation Links
Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
Date:4/28/2008

.

As expected, Gen-Probe's total revenues and net income in the first quarter of 2008 benefited from $16.4 million of royalty and license revenue received from Bayer, representing the third and final payment due in connection with the 2006 settlement of the companies' patent infringement litigation.

Detailed Results

Gen-Probe's clinical diagnostics sales in the first quarter of 2008 benefited from continued growth of the APTIMA Combo 2(R) assay, an amplified nucleic acid test (NAT) for simultaneously detecting Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC). Sales of this assay increased based on market share gains on both the Company's semi-automated instrument platform and on the high-throughput, fully automated TIGRIS(R) system. Revenue from the PACE(R) product line, the Company's non-amplified tests for the same microorganisms, declined in the first quarter compared to the prior year period, in line with Gen-Probe's expectations.

In blood screening, product sales in the first quarter of 2008 benefited from continued international expansion of the PROCLEIX ULTRIO assay, from higher pricing associated with U.S. commercial sales of the PROCLEIX WNV (West Nile virus) assay on the TIGRIS system, from the timing of product shipments, and from increased sales of TIGRIS instruments to Chiron. The Company's blood screening products are marketed worldwide by Chiron, a business unit of Novartis Vaccines and Diagnostics.

Product sales were, in millions:

Three Months Ended March 31,

2008 2007 Change

Clinical diagnostics $52.5 $47.6 10 %

Blood screening $49.0 $39.6 24 %

Total product sales $101.5 $87.2 16 %

Collaborative research revenues for the first quarter of 2008 were $2.5 million, compared to $2.4
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
2. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
3. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
4. Carl Hull Named President and Chief Operating Officer of Gen-Probe
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
6. Gen-Probe to Webcast Three Upcoming Presentations
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
9. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
10. CV Therapeutics Reports 2008 First Quarter Financial Results
11. Caliper Life Sciences Reports West Coast Consolidation of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... Diego, CA (PRWEB) November 17, 2014 Athena ... of Salk , Dr. Beverly Emerson, a professor in the ... of genes. Her most recent discovery points to an “off ... Dr. Emerson’s career and how her local research is making ... will present her findings and then join host Cheryl K. ...
(Date:11/18/2014)... Georgia (PRWEB) November 18, 2014 ... (Melbourne, Australia) recently formed a partnership with researchers ... Swinburne University of Technology, and the USDA’s Forest ... components reinforced with nanocellulose. Nanocellulose is a rapidly ... goal of the project is to replace heavy ...
(Date:11/18/2014)... 18, 2014 2014 Deep ... is professional and in-depth report on Polytetrahydrofuran ... information, including its definition, characterization, application, and ... This exploration covers the worldwide business investigation, ... examination covering macroeconomic environment & financial circumstance ...
(Date:11/18/2014)... Nev. , Nov. 18, 2014 PDL ... announced that in connection with the acquisition of Durata ... million in connection with the termination of PDL,s credit ... principal amount outstanding of $40 million, accrued interest, and ... PDL entered into a structured financing transaction with Durata ...
Breaking Biology Technology:American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2
... Genesis Biopharma, Inc. (OTC Bulletin Board: ... today announced that President and CEO Robert Brooke will ... Forum Biotech, Healthcare & Pharma Virtual Conference.  The webcast ... p.m. Eastern time (10:00 a.m. Pacific time) by visiting ...
... University have discovered new properties in a material that ... for pollution-free electricity production. The discovery, posted online ... the journal Nature Materials , reveals that energy-carrying ... the order of a thousand times farther in organic ...
... 8 IntegenX, Inc. (IXI) today announced that ... the Defense Threat Reduction Agency (DTRA) of the ... Integrated Sample-to-Sequence (ISS) system for rapid detection and ... relevant bacteria and viruses, and emerging pathogens. IntegenX ...
Cached Biology Technology:Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13 2Rutgers discovery paves way for development of efficient, inexpensive plastic solar cells 2IntegenX Awarded DTRA Contract to Develop Pathogen Detection and Identification Platform 2
(Date:11/3/2014)... DUBLIN , Nov. 3, 2014 Research ... report "Cell Therapy - Technologies, Markets and Companies" ... evaluates cell therapy technologies and methods, which have already started ... Hematopoietic stem cell transplantation is replacing the old fashioned bone ... described. Cell therapy is bound to become a part of ...
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
(Date:11/2/2014)... fascinating to put a flashlight up to our palms ... University in St. Louis engineers are using a similar ... improve imaging of cancerous tissues and to develop potential ... Beare Distinguished Professor of Biomedical Engineering at the School ... time-reversal technology that allows researchers to better focus light ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2Improving imaging of cancerous tissues by reversing time 2
... Boston Universitys College of Engineering may have discovered ... defeating so-called superbugs, bacteria that have developed resistance ... previously unknown chain of events occurring in bacteria ... research. Currently, three classes of bactericidal ...
... Efforts to make open-heart surgery a minimally invasive ... Institutes of Health Bioengineering Research Partnership award. Professor ... cardiac surgeon Pedro del Nido, M.D., at Childrens ... Inc. (Van Nuys, CA) will collaborate to develop ...
... says, is an essential peptide factor for the growth ... that this growth factor is important for the nervous ... in the October 7 issue of the World Journal ... about this growth factor: NGF is positively related with ...
Cached Biology News:Boston University biomedical engineers find chink in bacteria's armor 2Boston University biomedical engineers find chink in bacteria's armor 3Minimally invasive heart surgery research wins NIH award 2Targeting nerve growth factor may cure liver cancer 2
... weight determinations for petroleum-based applications. Multiple solvents can be used, such as water, benzene, formamide, ... ... ... ...
Fast, sensitive quantitation of total MEK 1/2 concentration....
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
... Automatic High Sensitivity Laboratory Osmometer for 50 L samples. Operating head automatically rises at the end of ... ... ... ...
Biology Products: